Latest Insights - page 23 | BiopharmaTrend

Kriya Raises $313 Million to Advance Gene Therapy Programs

Kriya Therapeutics has secured $313.3 million in new financing, according to a recent SEC filing. The filing did not outline neither the planned use of the funds, nor the names …

Continue ›››

AI Drug Developer Insilico Medicine Readies Brain-Penetrant Therapy For Parkinson’s Trials

Insilico Medicine reports it has finished IND-enabling work for ISM8969, an oral, blood-brain-barrier-penetrant NLRP3 inhibitor and aims to file an IND in Q4 2025 to start clinical evaluation in Parkinson’s disease. In …

Continue ›››

Eli Lilly Signs $1.3 Billion AI Drug Discovery Deal with Superluminal

Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines valued at up to $1.3 billion to discover small-molecule drugs for obesity and cardiometabolic diseases. The agreement gives Lilly …

Continue ›››

Schrödinger Ends CDC7 Inhibitor Program Following Two Patient Deaths in AML Trial

Schrödinger, founded in 1990 and known for its physics-based computational platform used in drug and materials discovery, has halted development of its experimental CDC7 inhibitor SGR-2921 after the drug was …

Continue ›››

Lantern Pharma Reports on Q2: Clinical Trials & New AI Prediction Tools

Dallas-based Lantern Pharma reported Q2 2025 results, marking progress across its oncology pipeline and AI drug development platform. The company completed Phase 1a enrollment for LP-184 in 65 patients with …

Continue ›››

Digital Pathology: Slides, AI, & Challenges

Pathology has progressed from glass slides to AI-driven digital diagnostics, promising to transform disease detection while facing adoption and market challenges Bo Wang, Head of Biomedical AI at Xaira Therapeutics, puts it …

Continue ›››

FDA Grants De Novo Authorization to ArteraAI’s Multimodal AI Prostate Cancer Risk Software

The U.S. Food and Drug Administration has granted De Novo authorization to ArteraAI Prostate, a multimodal artificial intelligence (MMAI) software developed by Artera, Los Altos, California headquartered precision medicine company, …

Continue ›››

PolarisQB Launches Quantum-AI Drug Discovery Platform for Beta Testing

Polaris Quantum Biotech (PolarisQB) has launched QuADD (Quantum-Aided Drug Design), a SaaS platform combining quantum computing and AI for early-stage drug discovery. The company is opening a beta program for …

Continue ›››

Gameto Gets $44M to Complete U.S. Phase 3 Trial of Stem Cell-Derived Ex Vivo Egg Maturation Therapy

Gameto has raised $44 million in a Series C round led by Overwater Ventures, bringing total funding to $127 million. The financing supports the company’s Phase 3 trial of Fertilo, …

Continue ›››

Doximity Buys Pathway Medical for $63M, Expands AI Suite for Physicians

Doximity, a San Francisco based digital health company, has acquired Montreal-based Pathway Medical in a deal valued at up to $63 million to strengthen its healthcare artificial intelligence capabilities. The …

Continue ›››

Asimov to Apply AI-Driven CHO Expression Platform in BARDA-BioMaP Filovirus Antibody Manufacturing

Asimov will lead a project under the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), part of the Administration …

Continue ›››

Tahoe Therapeutics Raises $30 Million to Expand Single-Cell Data Production for AI Models

Tahoe Therapeutics has raised $30 million in Series A financing, increasing total funding to $42 million and valuing the Palo Alto-based company at $120 million. The round was led by …

Continue ›››